The drug is being developed for metastatic non-small cell lung cancer (NSCLC) in patients whose tumours have an HER2 mutation and with disease progression on or after platinum-based therapy
Read More
Lynparza has been cleared for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
Read More
Patients achieved a disease control rate of 97.3%
Read More
AstraZeneca and Daiichi Sankyo’s trastuzumab deruxtecan has taken a step closer to US approval having been accepted for priority review by the US Food and Drug Administration (FDA) for breast cancer.
Read More
The drug has been granted US FDA Breakthrough Therapy Designation and Fast Track Designation.
Read More
The collaboration is aligned with AstraZeneca’s science-led strategy in oncology.
Read More
